N. Zaour

Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n = 135),

PSS21 Evaluation of Health Utility in Patients With Retinal Vein Occlusion

2,092; normal/mild loss (n = 88),

A NOVEL METHOD USING PRESCRIPTION TREATMENT PATTERNS TO ESTIMATE HEART FAILURE PREVALENCE IN CANADA

1,776; moderate loss (n = 13),

PREVALENCE, INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA IN A REPRESENTATIVE CANADIAN COHORT

1,845; and severe loss/nearly blind (n = 34),

Real-World Utilization Data Over 4 Years of Ranibizumab Injections for the Treatment of Wet Age-Related Macular Degeneration in Canada

3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind. Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity.